VEA
TARS icon

Virtus ETF Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History

Virtus ETF Advisers’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,845
Closed -$379K – 760
2024
Q4 		$379K Sell
6,845
-3,093
-31% -$140K 0.15% 188
2024
Q3 		$327K Hold
9,938
– – 0.15% 225
2024
Q2 		$270K Sell
9,938
-9,990
-50% -$336K 0.13% 240
2024
Q1 		$724K Buy
19,928
+2,867
+17% +$84.3K 0.38% 120
2023
Q4 		$345K Buy
+17,061
New +$285K 0.22% 191
2021
Q4 		– Sell
-6,008
Closed -$129K – 396
2021
Q3 		$129K Sell
6,008
-311
-5% -$7.7K 0.06% 365
2021
Q2 		$183K Buy
+6,319
New +$197K 0.08% 384

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Virtus ETF Advisers's TARS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 6,845 shares — an estimated $379K sold.

Virtus ETF Advisers first reported a position in TARS in Q2 2021 and held it in 7 quarters. The position peaked at $724K in Q1 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,845 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $379K.
  • Virtus ETF Advisers first reported a position in Tarsus Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Virtus ETF Advisers's Tarsus Pharmaceuticals position peaked at $724K in Q1 2024.
  • 194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.